Clinical Trial Update: A Phase II Study of the Combination of Pembrolizumab and ATRA Combination Treatment of Relapsed HL and B-NHL [Phase 2]

View source ↗

Summary

A Phase II trial evaluating the combination of pembrolizumab and all-trans retinoic acid for relapsed or refractory Hodgkin lymphoma and non-Hodgkin lymphoma is…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• All-trans Retinoic Acid (all-trans retinoic acid)
• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Rita Assi | Conditions: Relapsed Hodgkin Lymphoma, Refractory Hodgkin Lymphoma | Phase 2 | Status: RECRUITING